Ilacirnon

N/A

Report date: 2025/02/19 20:00:46
NME

Base Information

Drug NameIlacirnon
Drug Alias NameCCX-140CCX-140B
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Glomerulosclerosis, Focal SegmentalDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[13] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChemocentryx
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen IncVifor Pharma
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Glomerulosclerosis, Focal SegmentalDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A